ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0534

Lymphatic Dysfunction in Murine Lupus Photosensitivity

SLE – Animal Models Poster (0534–0540)

8:30AM-10:30AM: Abstract Number: 0765

Male Juvenile Systemic Sclerosis Patients Have More Severe Disease: Results from the International Juvenile Scleroderma Inception Cohort

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: Abstract Number: 0716

Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0713

MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0744

MDHAQ (Multidimensional Health Assessment Questionnaire) and PROMIS-29 (patient-reported Outcomes Measurement Information System) Domains for Physical Function, Pain, Fatigue, Anxiety, Depression, Sleep, and Ability to Participate Provide Virtually Identical Information

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0906

Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Abstract Number: 0767

Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: Abstract Number: 0551

Metabolic Intermediate Dimethyl-Alpha-Ketoglutarate Is a Novel Repressor of Pathogenic Myofibroblast Reprogramming and Skin Fibrosis in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

8:30AM-10:30AM: Abstract Number: 0923

Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0705

Mitochondrial Calcification-Induced Inflammation in Human Skeletal Muscle and Immune Cells

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0840

Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0531

Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0791

Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0898

MRI Vertebral Corner Inflammation and Fat Deposition Are Associated with Whole Spine Low Dose CT Detected Syndesmophytes: A Multilevel Analysis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Abstract Number: 0883

Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.